hepatitis a hepatitis a hepatitis a is an infectious disease of the liver caused by hepatovirus a (hav); it is a type of viral hepatitis. many cases have few or no symptoms, especially in the young. the time between infection and symptoms, in those who develop them, is 2–6 weeks. when symptoms occur, they typically last 8 weeks and may include nausea, vomiting, diarrhea, jaundice, fever, and abdominal pain. around 10–15% of people experience a recurrence of symptoms during the 6 months after the initial infection. acute liver failure may rarely occur, with this being more common in the elderly. hepatitis aother namesinfectious hepatitisa case of jaundice caused by hepatitis aspecialtyinfectious disease, gastroenterologysymptomsnausea, vomiting, diarrhea, dark urine, jaundice, fever, abdominal paincomplicationsacute liver failureusual onset2–6 weeks after infectionduration8 weekscauseseating food or drinking water contaminated with hepatovirus a infected fecesdiagnostic methodblood testspreventionhepatitis a vaccine, hand washing, properly cooking foodtreatmentsupportive care, liver transplantationfrequency114 million symptomatic and nonsymptomatic (2015)deaths11,200 it is usually spread by eating food or drinking water contaminated with infected feces. undercooked or raw shellfish are relatively common sources. it may also be spread through close contact with an infectious person. while children often do not have symptoms when infected, they are still able to infect others. after a single infection, a person is immune for the rest of their life. diagnosis requires blood testing, as the symptoms are similar to those of a number of other diseases. it is one of five known hepatitis viruses: a, b, c, d, and e. the hepatitis a vaccine is effective for prevention. some countries recommend it routinely for children and those at higher risk who have not previously been vaccinated. it appears to be effective for life. other preventive measures include hand washing and properly cooking food. no specific treatment is available, with rest and medications for nausea or diarrhea recommended on an as-needed basis. infections usually resolve completely and without ongoing liver disease. treatment of acute liver failure, if it occurs, is with liver transplantation. globally, around 1.4 million symptomatic cases occur each year and about 114 million infections (symptomatic and asymptomatic). it is more common in regions of the world with poor sanitation and not enough safe water. in the developing world, about 90% of children have been infected by age 10, thus are immune by adulthood. it often occurs in outbreaks in moderately developed countries where children are not exposed when young and vaccination is not widespread. acute hepatitis a resulted in 11,200 deaths in 2015. world hepatitis day occurs each year on july 28 to bring awareness to viral hepatitis. signs and symptoms early symptoms of hepatovirus a infection can be mistaken for influenza, but some people, especially children, exhibit no symptoms at all. symptoms typically appear 2–6 weeks (the incubation period) after the initial infection. about 90% of children do not have symptoms. the time between infection and symptoms, in those who develop them, is 2–6 weeks, with an average of 28 days. the risk for symptomatic infection is directly related to age, with more than 80% of adults having symptoms compatible with acute viral hepatitis and the majority of children having either asymptomatic or unrecognized infections. symptoms usually last less than 2 months, although some people can be ill for as long as 6 months: fatigue fever nausea appetite loss jaundice, a yellowing of the skin or the whites of the eyes owing to hyperbilirubinemia bile is removed from the bloodstream and excreted in the urine, giving it a dark amber color diarrhea light or clay-colored faeces (acholic faeces) abdominal discomfort extrahepatic manifestations joint pains, red cell aplasia, pancreatitis and generalized lymphadenopathy are the possible extrahepatic manifestations. kidney failure and pericarditis are very uncommon. if they occur, they show an acute onset and disappear upon resolution of the disease. virology hepatovirus a electron micrograph of hepatovirus a virions virus classification (unranked): virus realm: riboviria kingdom: orthornavirae phylum: pisuviricota class: pisoniviricetes order: picornavirales family: picornaviridae genus: hepatovirus species: hepatovirus a synonyms hepatitis a virus human hepatitis a virus simian hepatitis a virus taxonomy hepatovirus a is a species of virus in the order picornavirales, family picornaviridae, genus hepatovirus. humans and other vertebrates serve as natural hosts. nine members of hepatovirus are recognized. these species infect bats, rodents, hedgehogs, and shrews. phylogenetic analysis suggests a rodent origin for hepatitis a. a member virus of hepatovirus b (phopivirus) has been isolated from a seal. this virus shared a common ancestor with hepatovirus a about 1800 years ago. another hepatovirus – marmota himalayana hepatovirus – has been isolated from the woodchuck marmota himalayana. this virus appears to have had a common ancestor with the primate-infecting species around 1000 years ago. genotypes one serotype and seven different genetic groups (four human and three simian) have been described. the human genotypes are numbered i–iii. six subtypes have been described (ia, ib, iia, iib, iiia, iiib). the simian genotypes have been numbered iv–vi. a single isolate of genotype vii isolated from a human has also been described. genotype iii has been isolated from both humans and owl monkeys. most human isolates are of genotype i. of the type i isolates subtype ia accounts for the majority. the mutation rate in the genome has been estimated to be 1.73–9.76 × 10−4 nucleotide substitutions per site per year. the human strains appear to have diverged from the simian about 3600 years ago. the mean age of genotypes iii and iiia strains has been estimated to be 592 and 202 years, respectively. structure hepatovirus a is a picornavirus; it is not enveloped and contains a positive-sense, single-strand of rna packaged in a protein shell. only one serotype of the virus has been found, but multiple genotypes exist. codon use within the genome is biased and unusually distinct from its host. it also has a poor internal ribosome entry site. in the region that codes for the hav capsid, highly conserved clusters of rare codons restrict antigenic variability. genusstructuresymmetrycapsidgenomic arrangementgenomic segmentation hepatovirusicosahedralpseudo t=3nonenvelopedlinearmonopartite replication cycle vertebrates such as humans serve as the natural hosts. transmission routes are fecal-oral and blood. following ingestion, hav enters the bloodstream through the epithelium of the oropharynx or intestine. the blood carries the virus to its target, the liver, where it multiplies within hepatocytes and kupffer cells (liver macrophages). viral replication is cytoplasmic. entry into the host cell is achieved by attachment of the virus to host receptors, which mediates endocytosis. replication follows the positive-stranded rna virus replication model. translation takes place by viral initiation. the virus exits the host cell by lysis and viroporins. virions are secreted into the bile and released in stool. hav is excreted in large numbers about 11 days prior to the appearance of symptoms or anti-hav igm antibodies in the blood. the incubation period is 15–50 days and risk of death in those infected is less than 0.5%. within the liver hepatocytes, the rna genome is released from the protein coat and is translated by the cell's own ribosomes. unlike other picornaviruses, this virus requires an intact eukaryotic initiation factor 4g (eif4g) for the initiation of translation. the requirement for this factor results in an inability to shut down host protein synthesis, unlike other picornaviruses. the virus must then inefficiently compete for the cellular translational machinery, which may explain its poor growth in cell culture. presumably for this reason, the virus has strategically adopted a naturally highly deoptimized codon usage with respect to that of its cellular host. precisely how this strategy works is not quite clear yet. no apparent virus-mediated cytotoxicity occurs, presumably because of the virus' own requirement for an intact eif4g, and liver pathology is likely immune-mediated. genushost detailstissue tropismentry detailsrelease detailsreplication siteassembly sitetransmission hepatovirushumans; vertebrateslivercell receptor endocytosislysiscytoplasmcytoplasmoral-fecal; blood transmission the virus spreads by the fecal–oral route, and infections often occur in conditions of poor sanitation and overcrowding. hepatitis a can be transmitted by the parenteral route, but very rarely by blood and blood products. food-borne outbreaks are common, and ingestion of shellfish cultivated in polluted water is associated with a high risk of infection. about 40% of all acute viral hepatitis is caused by hav. infected individuals are infectious prior to onset of symptoms, roughly 10 days following infection. the virus is resistant to detergent, acid (ph 1), solvents (e.g., ether, chloroform), drying, and temperatures up to 60 °c. it can survive for months in fresh and salt water. common-source (e.g., water, restaurant) outbreaks are typical. infection is common in children in developing countries, reaching 100% incidence, but following infection, lifelong immunity results. hav can be inactivated by chlorine treatment (drinking water), formalin (0.35%, 37 °c, 72 hours), peracetic acid (2%, 4 hours), beta-propiolactone (0.25%, 1 hour), and uv radiation (2 μw/cm2/min). hav can also be spread sexual contact specifically oroanal sexual acts. in developing countries, and in regions with poor hygiene standards, the rates of infection with this virus are high and the illness is usually contracted in early childhood. as incomes rise and access to clean water increases, the incidence of hav decreases. in developed countries, though, the infection is contracted primarily by susceptible young adults, most of whom are infected with the virus during trips to countries with a high incidence of the disease or through contact with infectious persons. humans are the only natural reservoir of the virus. no known insect or other animal vectors can transmit the virus. a chronic hav state has not been reported. diagnosis serum igg, igm, and alt following hepatovirus a infection although hav is excreted in the feces towards the end of the incubation period, specific diagnosis is made by the detection of hav-specific igm antibodies in the blood. igm antibody is only present in the blood following an acute hepatitis a infection. it is detectable from 1–2 weeks after the initial infection and persists for up to 14 weeks. the presence of igg antibodies in the blood means the acute stage of the illness has passed and the person is immune to further infection. igg antibodies to hav are also found in the blood following vaccination, and tests for immunity to the virus are based on the detection of these antibodies. during the acute stage of the infection, the liver enzyme alanine transferase (alt) is present in the blood at levels much higher than is normal. the enzyme comes from the liver cells damaged by the virus. hepatovirus a is present in the blood (viremia) and feces of infected people up to 2 weeks before clinical illness develops. prevention for information about the vaccine, its properties, and its application, see hepatitis a vaccine. hepatitis a can be prevented by vaccination, good hygiene, and sanitation. vaccination the two types of vaccines contain either inactivated hepatovirus a or a live but attenuated virus. both provide active immunity against a future infection. the vaccine protects against hav in more than 95% of cases for longer than 25 years. in the united states, the vaccine developed by maurice hilleman and his team was licensed in 1995, and the vaccine was first used in 1996 for children in high-risk areas, and in 1999 it was spread to areas with elevating levels of infection. the vaccine is given by injection. an initial dose provides protection lasting one year starting 2–4 weeks after vaccination; the second booster dose, given six to 12 months later, provides protection for over 20 years. the vaccine was introduced in 1992 and was initially recommended for persons at high risk. since then, bahrain and israel have embarked on elimination programmes. australia, china, belarus, italy, spain, and the united states have started similar programmes. the incidence of hepatitis a where widespread vaccination has been practised has decreased dramatically. in china and the united states, the incidence of hepatitis a has decreased by 90% since 1990. in the united states, vaccination of children is recommended at 1 and 2 years of age; hepatitis a vaccination is not recommended in those younger than 12 months of age. it is also recommended in those who have not been previously immunized and who have been exposed or are likely to be exposed due to travel. the cdc recommends vaccination against infection for men who have sex with men. treatment no specific treatment for hepatitis a is known. recovery from symptoms following infection may take several weeks or months.